FDA’s inaction on CBD regulations means more marijuana questions for Congress

January 27, 2023 · MJ Biz Daily

The U.S. Food and Drug Administration’s announcement Thursday that it won’t regulate products containing CBD and will instead pass that buck to Congress means the preservation of the current, uneasy status quo for now.

It will also mean more work for an increasingly fractious Congress – and further uncertainty for companies deciding whether to enter the $4 billion-plus CBD business. 

In addition to grappling with broader marijuana policy reform – including access to banking, tax relief and the question of federal legalization – Congress must decide what to do with intoxicating hemp-derived cannabinoids such as delta-8 and delta-10 THC.

“I don’t think this changes anything for now, whether you’re in the CBD space, the delta-9 space or the delta-8 space – at least not for today,” said Jonathan Havens, a former counsel at the FDA and now a Baltimore-based attorney who co-chairs the cannabis law practice at Saul Ewing.

“The FDA has been saying all along, ‘We don’t want to deal with this, Congress needs to get involved.’

“Now it depends what Congress does with it.”

For now, the FDA has taken a mostly hands-off approach regarding CBD products, sending enforcement letters only to companies marketing products using unfounded medical claims.

Such claims violate the federal Food, Drug, and Cosmetic Act.

That won’t change.

Farm Bill could come into play

But what cannabinoids might be allowed in gummies, drinks or other products is one of the questions that could be answered at the same time Congress negotiates a new version of the 2018 Farm Bill, which expires this year.

A massive piece of legislation that covers farm subsidies, food-stamp benefits and many other topics, the 2018 Farm Bill – promoted by then-Senate Majority Leader Mitch McConnell and signed into law by former President Donald Trump –  legalized hemp production nationwide.

In so doing, it also predicated the CBD boom and, along with it, the rise of novel intoxicating cannabinoids derived from hemp.

Since that time, the FDA has been on notice to figure out how to regulate an onslaught of products containing CBD and other cannabinoids derived from hemp.

Rather than do that, the FDA declined Thursday to regulate CBD products including other food supplements, saying its existing regulatory frameworks were inadequate – and that Congress should tell the FDA what to do.

In a statement Thursday, Dr. Janet Woodcock, the FDA’s principal deputy commissioner, said the agency “has concluded that a new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks.”

“The use of CBD raises various safety concerns, especially with long-term use,” Woodcock added.

“The agency is prepared to work with Congress on this matter.”

Though Woodcock did not mention other cannabinoids that have gained popularity over the past four years – including delta-8 and delta-10 THC, which can be derived from CBD via a chemical process, as well as delta-9 THC – the FDA has noted the “serious health risks” posed by so-called alternative cannabinoids and has been tracking reports of adverse health effects.

That means either the next Farm Bill or a separate stand-alone measure would likely have to address those compounds, said Shawn Hauser, a partner at Vicente Sederberg who chairs the Denver firm’s Hemp and Cannabinoids Department.

For that, Congress does already have a model to follow.

Several states, including Colorado and Utah, have regulated hemp products in a manner similar to how they oversee marijuana.

Trade groups ‘disappointed’

Trade associations representing hemp growers and product manufacturers said Thursday they were “disappointed” by the FDA’s announcement, hoping instead the agency would have provided clear rules rather than punting the question.

At the same time, the situation will insert a sense of urgency into ongoing lobbying efforts, said Michael Bronstein, the president of the Washington DC-based American Trade Association for Cannabis and Hemp.

“We will diligently work with Congress to develop and advance a pathway that protects consumers, creates certainty in the marketplace for CBD goods, and provides for sound regulation,” he said.

In the meantime, the uncertainty for existing product makers will continue.

Congress could decide that the FDA is the appropriate agency to also regulate cannabis products.

Or lawmakers could also decide an entirely new agency should be responsible for regulating hemp-derived cannabinoids – an unexpected but irreversible side effect of the Farm Bill revision that’s now been added to Congress’s burgeoning to-do list.

“I think the reality is, people want access to all different types of cannabis, both medicinally as well as recreationally, and people are also feeling that it has benefits as a supplement to their diet,” Hauser said.

“And in states like Texas and Tennessee and Kentucky, this is the only way for people to get access to them.

“This could be something that helps some of the states understand that legalizing cannabis and regulating it and imposing product safety standards is a better approach than prohibition.” (Full Story)

In categories:CBD Legal Politics
Next Post

Americans Want Marijuana Less Strictly Regulated While Backing Tighter Rules On Teslas, Crypto And Twitter, Poll Finds

Americans say that marijuana should be less strictly regulated than it is now, while also favoring greater regulations on cryptocurrencies, social media, electric vehicles and coal, according to a new poll. The Harvard CAPS-Harris Poll surveyed voters about a wide…
Previous Post

Study: Cannabis Legalization Does Not Lead to Increased Use of Other Drugs

A new report found cannabis legalization does not lead to an increase in substance use disorders or the increased use of illicit drugs. Cannabis legalization had not led to an increase in substance use disorders or increased use of other…
Random Post

More than 40 vendors, 29 speakers set to appear at N.J.’s biggest cannabis business conference

On March 8, the state’s largest and most comprehensive cannabis business conference will feature more than 40 vendors and 29 speakers, offering just about everything a Garden State legal weed operator needs to know and the people they need to meet to…
Random Post

Kentucky Senate Committee Approves Medical Marijuana Legalization Bill

A Kentucky Senate committee on Tuesday approved a bill to legalize medical marijuana in the state. The Senate Licensing & Occupations Committee passed the legislation from Sen. Stephen West (R) and 12 other senators in a 8-3 vote. It now…
Random Post

Is Cannabis Legalization Stalling Out Across America? - Rec Weed Fails in Arkansas, North Dakota, South Dakota, and Oklahoma

As the winds of change blow across the United States, many states have lifted their bans on recreational cannabis. However, not every state has embraced the green wave with open arms. Despite the growing popularity of cannabis and its proven medical…
Random Post

Federal Marijuana Trafficking Cases Declined Again In 2022 Amid Legalization Movement, Federal Report Shows

Federal marijuana trafficking cases continued to decline in 2022, according to the latest annual report from the U.S. Sentencing Commission (USSC). As more states have moved to legalize cannabis and federal priorities have shifted, prosecutions for marijuana-related cases have significantly declined…